Brief: Astrazeneca Pharma India Gets Permission To Import Durvalumab
23/09/2024 14:58
Sept 23 (Reuters) - Astrazeneca Pharma India Ltd
ASTR.NS :
* RECEIVED PERMISSION TO IMPORT FOR SALE AND DISTRIBUTION OF
DURVALUMAB
* RECEIPT OF THIS PERMISSION PAVES WAY FOR LAUNCH OF
DURVALUMAB IN
INDIA
Source text for Eikon: ID:nNSE90kGdc
Further company coverage: ASTR.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan
India's Astrazeneca Pharma logs worst slide in two months on quarterly profit drop
Brief: Astrazeneca Pharma India March-Quarter PAT 448.8 Million Rupees
Brief: Astrazeneca Pharma India Recommends Dividend Of 36 Rupees Per Equity Share For Fy2025-26
Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab (Imfinzi) For Additional Indication